Compared side by side
Orforglipron vs tirzepatide: how they differ
The short answer
Orforglipron is a small molecule (not a peptide) that acts on one receptor, GLP-1, taken as a daily tablet with or without food; tirzepatide is a weekly shot that activates the GLP-1 and GIP receptors. Both are FDA-approved for weight management, orforglipron as Foundayo since April 2026 and tirzepatide as Zepbound. In their own trials, orforglipron’s top dose averaged about 11% weight loss at 72 weeks, and tirzepatide’s 15 mg up to 22.5% at 72 weeks (SURMOUNT-1).
Side by side
| Compared | Orforglipron | Tirzepatide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Foundayo, LY3502970, Orfo | Mounjaro, Zepbound, LY3298176 |
| What it is | A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. | The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). |
| How it works | Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily. | Dual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management. |
| Commonly reported | The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. | Very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound). |
| Studied range | FDA label: 0.8–17.2 mg, starting dose 0.8 mg. | FDA label: 2.5–15 mg, starting dose 2.5 mg. |
| How often | Daily | Weekly |
| Half-life | ~29–49 hours (FDA label; steady levels after about a week of daily tablets) | ~5 days (FDA label) |
| Route | Oral tablet | SubQ injection |
| Typical run | FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off. | FDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping | Nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue |
- Category
- OrforglipronMetabolic & GLP-1
- TirzepatideMetabolic & GLP-1
- Also known as
- OrforglipronFoundayo, LY3502970, Orfo
- TirzepatideMounjaro, Zepbound, LY3298176
- What it is
- OrforglipronA GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management.
- TirzepatideThe first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
- How it works
- OrforglipronSmall-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily.
- TirzepatideDual GIP/GLP-1 receptor agonist. Significantly reduces body weight through appetite suppression, slowed gastric emptying, and improved insulin sensitivity. Approved for T2DM and obesity management.
- Commonly reported
- OrforglipronThe easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial.
- TirzepatideVery strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).
- Studied range
- OrforglipronFDA label: 0.8–17.2 mg, starting dose 0.8 mg.
- TirzepatideFDA label: 2.5–15 mg, starting dose 2.5 mg.
- How often
- OrforglipronDaily
- TirzepatideWeekly
- Half-life
- Orforglipron~29–49 hours (FDA label; steady levels after about a week of daily tablets)
- Tirzepatide~5 days (FDA label)
- Route
- OrforglipronOral tablet
- TirzepatideSubQ injection
- Typical run
- OrforglipronFDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off.
- TirzepatideFDA-approved for ongoing use. Titrate slowly upward. Community maintains on minimum effective dose.
- Evidence
- OrforglipronEstablished: clinical trials or FDA-approved use exists
- TirzepatideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- OrforglipronNausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping
- TirzepatideNausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Orforglipron
- Day 1–30 · 0.8 mg The 0.8 mg start
- Day 31–60 · 2.5 mg 2.5 mg, the second step
- Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
- Day 91+ · 9 mg 9 mg, an optional step
- Day 121+ · 14.5 mg 14.5 mg, the step before the top
- Day 151+ · 17.2 mg 17.2 mg, the top dose
Tirzepatide
- Day 1–28 · 2.5 mg Getting your gut acclimated
- Day 29–56 · 5 mg First therapeutic dose — weight drops
- Day 57–112 · 7.5 mg Dual agonism in full effect
- Day 113–168 · 12.5 mg Max titration reached
- Day 169–504 Weeks 24 to 72: where most people plateau
- Day 365+ A maintenance medication, not a course
Questions people ask
How long do orforglipron and tirzepatide last?
The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets). The half-life of tirzepatide is ~5 days (FDA label).
How often are orforglipron and tirzepatide taken?
Orforglipron: daily. Route: Oral tablet. Tirzepatide: weekly. Route: SubQ injection.
How are orforglipron and tirzepatide dosed in research?
The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose. The FDA label range for tirzepatide is 2.5–15 mg, with a 2.5 mg starting dose.
What are the common side effects of orforglipron and tirzepatide?
For orforglipron, the library lists: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping. For tirzepatide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, fatigue.